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Randomized controlled trial of prophylactic repair of hemodial-
ysis arteriovenous graft stenosis.
Background. Previous nonrandomized studies suggest that
prophylactic repair of hemodialyisis arteriovenous (AV) graft
stenosis reduces thrombosis rates and increases cumulative
graft survival. The present study is a randomized trial compar-
ing prophylactic repair of AV graft stenosis with repair at the
time of thrombosis.
Methods. Sixty-four patients with elevated static venous pres-
sure measured in an upper extremity AV graft were randomized
to Intervention or Observation. Monthly static venous pres-
sure/systolic blood pressure ratios (SVPR) were determined
for all patients throughout the duration of study participation.
Patients in the Intervention group underwent angiography and
repair of identified stenoses if the monthly SVPR was elevated
(≥0.4). Patients in the Observation group underwent stenosis
repair only in the event of access thrombosis or clinical evi-
dence of access dysfunction. The primary end point was access
abandonment.
Results. Access abandonment occurred in 14 patients in the
Intervention group and 14 patients in the Observation group
during the 3.5-year study period. Time to access abandon-
ment did not differ significantly between the treatment groups
(hazard ratio for randomization to Intervention 1.75, 95% CI
0.80–3.82, P = 0.16). The proportion of patients with a throm-
botic event was greater in the Observation group (72%) than
in the Intervention group (44%) (P = 0.04), but overall throm-
bosis rates were similar in the groups.
Conclusion. Compared with a strategy of observation and
repair of accesses only in the event of thrombosis, prospective
static venous pressure monitoring with prophylactic stenosis
repair did not prolong graft survival.
Vascular access failure is one of the greatest sources
of morbidity for chronic hemodialysis patients. Sixteen
to 25% of hospital admissions among United States
end-stage renal disease (ESRD) patients are related to
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vascular access complications, and the associated cost
has been estimated to be approximately one billion dol-
lars per year [1, 2]. The most frequent cause of arteriove-
nous (AV) access failure is thrombosis that occurs as a
result of stenosis at or near the venous anastomosis. Most
stenotic lesions can be corrected, at least temporarily, by
percutaneous transluminal angioplasty (PTA) or surgery.
Several studies have suggested that early detection and
repair of stenosis can prevent access thrombosis [3–8].
Reductions in access thrombosis rates to approximately
0.2 to 0.3 per patient-year have been reported after im-
plementation of access monitoring and repair programs
[3, 4, 7, 8]. In addition, it has been suggested that prophy-
lactic approaches reduce overall access-related costs [8].
Such findings have led to widespread recommendations
that accesses be monitored regularly for the development
of stenosis, and repaired with percutaneous angioplasty
or surgery before thrombosis [9].
Although the benefits of prophylactic access repair ap-
pear substantial, limitations of previous studies warrant
consideration. Nearly all of the demonstrations of re-
ductions in thrombosis rates with prophylactic stenosis
repair are nonrandomized studies that either used histor-
ical controls or compared treatment approaches applied
during consecutive time periods. Indeed, one previous
randomized trial found that prophylactic repair failed to
prolong primary patency of AV grafts except in a subset
of “virgin” grafts (i.e., grafts with no previous surgical or
percutaneous procedures) [10, 11], and a second random-
ized trial found similar thrombosis rates among patients
undergoing access repair in response to reduced access
blood flow and those getting repair based upon routine
clinical monitoring [12]. Furthermore, most of the previ-
ous studies evaluated the impact of prophylactic repair on
access thrombosis but not access survival. In those stud-
ies that did find a benefit of prophylactic repair on access
survival, the use of historical controls from the mid- or
late-1980s may have resulted in an overestimation of ac-
cess loss from thrombosis in the current era of aggressive
salvage of thrombosed grafts [3, 4]. In order to more rig-
orously assess the effect of prophylactic repair on access
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survival we conducted a randomized trial comparing pro-
phylactic AV graft stenosis repair with stenosis repair at
the time of thrombosis.
METHODS
Participants
Patients were enrolled from two hemodialysis facil-
ities affiliated with Boston University Medical Cen-
ter and the Veterans Affairs (VA) Boston Healthcare
System. Chronic hemodialysis patients with an upper
extremity AV graft and elevated static venous pressure
ratio (SVPR) during monthly venous pressure monitor-
ing were eligible to participate. Exclusion criteria in-
cluded life expectancy of less than two years, anticipated
change in renal replacement modality or geographic
relocation, noncompliance with medical care, concurrent
participation in another intervention trial, allergy to ra-
diographic contrast material, and inability to give in-
formed consent. The AV graft had to have been placed at
least 30 days before enrollment. The study was approved
by the Institutional Review Boards of Boston University
Medical Center and the VA Boston Healthcare System.
All patients provided informed consent for participation
in the trial.
Randomization
Patients were randomized to the Intervention or Ob-
servation arm using a random number generator and a
permuted block scheme. Randomization was stratified by
study site. Neither the patients nor the study team mem-
bers were blinded to treatment assignment. However,
the radiologists and surgeons performing the interven-
tion procedures were unaware of treatment assignment.
Venous pressure measurements
Static venous pressure measurements were performed
in all patients during two consecutive dialysis sessions
each month as previously described [13]. Venous drip
chamber pressure and systemic blood pressure were ob-
tained 20 to 30 seconds after turning off the dialysis blood
pump using the dialysis machine digital pressure display.
The intra-access venous pressure was calculated as fol-
lows: PIA = PDC + dH, where PIA (mm Hg) is intra-
access pressure, PDC (mm Hg) is venous drip chamber
pressure, and dH (cm) is the difference in height between
the venous drip chamber pressure transducer and the ve-
nous needle in the access. The static venous pressure ra-
tio (SVPR) refers to the intragraft pressure normalized
to systolic blood pressure: SVPR = PIA/SBP. All SVPR
measurements were made by a single member of the
study team. The monthly SVPR was the mean of the val-
ues obtained during the two consecutive dialysis sessions.
All patients were dialyzed with a Cobe Centrysystem 3
or Centrysystem 3 Plus machine (Cobe, Inc., Lakewood,
CO, USA). We defined an elevated SVPR as ≥0.4, the
value previously found to have the best predictive value
for access stenosis when venous pressure measurement
is normalized by systolic blood pressure [4]. The treating
nephrologists were informed when a patient was referred
for angiography because of an elevated SVPR, but other-
wise were not made aware of the monthly SVPR values.
Treatment arms
Patients randomized to the Intervention arm un-
derwent angiography within one week of an elevated
monthly SVPR. Two interventional radiologists per-
formed all of the studies at the Boston University
Medical Center site, and one interventional radiologist
performed all of the studies at the VA site. Access re-
pair was performed if a stenosis producing a reduction in
lumen diameter of 50% or greater was identified. PTA
was used to repair the stenosis at the time of angiogra-
phy unless the angiographer felt the lesion could not be
safely dilated. Surgical repair with patch angioplasty or
placement of a jump graft was used if PTA was unable to
be performed or was unsuccessful. Angiography was per-
formed within two weeks after surgical repair to confirm
that all identifiable stenoses were repaired. Angiography
and stenosis repair was repeated throughout the course
of the study whenever the monthly SVPR value was ≥0.4.
Patients with elevated SVPR but an angiogram that did
not reveal stenosis of 50% or greater underwent repeat
angiography only if SVPR remained elevated six months
later.
Patients randomized to the Observation arm had
monthly static venous monitoring performed, but did not
have angiography or access repair in response to an ele-
vated SVPR. Angiography and repair was allowed in the
Observation group patients for inadequate dialysis, arm
swelling, or other clinical evidence of access dysfunction.
The management of thrombotic events was the same in
both groups. In the event of thrombosis, restoration of ac-
cess patency was attempted with mechanical and/or phar-
macologic thrombolysis and PTA of identified stenoses,
or with surgical thrombectomy. Decisions about the ap-
proach to restoring patency or the need for access revi-
sion or new access creation were made by the patient’s
nephrologist, vascular surgeon, and interventional radi-
ologist, who were not specifically informed of the pa-
tient’s randomized treatment assignment. Participation
in the study ended at the time of access abandonment.
An access was considered abandoned when patency could
not be restored by radiologic or surgical intervention, or
when it was removed for infection, steal syndrome, or
pseudoaneurysm development. Revision of the access did
not constitute abandonment as long as either the original
venous or original arterial anastomosis was maintained.
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Decisions about access abandonment were made by the
patient’s physicians. In the event of access abandonment,
re-enrollment in the study after placement of a new AV
graft was not permitted.
Outcomes and sample size determination
The primary outcome was access abandonment as de-
fined above. Predefined secondary outcomes included
thrombotic events, access procedures, access infections,
central venous catheter placements, and death.
We anticipated that 57 patients per treatment group
would be required to detect a 33% reduction in the an-
nual cumulative incidence of access abandonment in the
Intervention arm using the log-rank test with 80% power
and a two-sided significance level of 0.05, and assuming
a 12-month access abandonment rate of 0.5 in the Obser-
vation group.
Data analysis
Baseline characteristics were compared using the Stu-
dent t test or the Mann-Whitney U test for continuous
variables, and Fisher exact test for categorical variables.
Kaplan-Meier analysis was used to depict access sur-
vival with comparison of survival using the log-rank test.
Crude and adjusted risks of access events were deter-
mined using Cox proportional-hazards regression. Rate
ratios and 95% conference intervals were calculated us-
ing exact probability model for the data with conditional
maximum-likelihood estimate. All analyses used a two-
tailed significance value of 0.05, and were performed us-
ing SPSS for Windows 10.0 software (SPSS, Inc., Chicago,
IL, USA), with the exception of the rate ratios, which
were performed using STATA 7.0 for Windows (Stata
Corporation, College Station, TX, USA). Analyses were
based on the intention to treat. The study was stopped at
42 months because a planned interim analysis revealed
futility of the intervention.
RESULTS
Patients
During 625 patient-months of static venous pressure
monitoring, 184 patients with elevated SVPR in an upper
extremity AV graft were identified (Fig. 1). Of these pa-
tients, 64 met the study eligibility criteria and agreed to
participate in the trial. Four patients who were random-
ized to the Intervention arm withdrew from the study be-
fore undergoing the first angiography study. Two other
patients in the Intervention arm withdrew: one after
9 months of participation, and the other after 22 months
of participation. All other patients remained in the study
until access abandonment, transplantation, transfer to an-
other facility, or death.
Baseline characteristics of the patients are summarized
in Table 1. The Intervention group had a greater pro-
portion of women than did the Observation arm. None
of the other baseline characteristics differed significantly
between the two groups. Median follow-up was 249 days
for patients in the Intervention group, and 503 days for
patients in the Observation group.
Access survival
Fourteen patients in the Intervention group and 14
patients in the Observation group reached the primary
end point of access abandonment. As shown in Figure 2,
time to access abandonment did not differ significantly
between the two groups, although there was a trend to-
ward better access survival in the Observation group. In
order to adjust for differences in patient characteristics
between the two treatment groups, a multivariable Cox
proportional hazards model was generated with the fol-
lowing covariates: sex, diabetes mellitus, peripheral vas-
cular disease, access location, and treatment assignment.
Of these covariates, sex was the only one that differed
significantly between the two treatment groups, with a
greater proportion of females in the Intervention group
than in the Observation group. Peripheral vascular dis-
ease, diabetes mellitus, and upper arm grafts were each
present in a greater proportion of the Intervention group
than Observation group patients, but the differences did
not reach statistical significance. In the adjusted analysis
(Table 2), randomization to the Intervention arm was an
independent predictor of access abandonment (hazard
ratio 2.91, 95% CI 1.17–7.20, P = 0.02).
Accesses were abandoned because of inability to
restore patency following a thrombotic event, access in-
fection, vascular steal syndrome, pseudoaneurysm forma-
tion, and access rupture during prophylactic angioplasty
(Table 3). The time to access abandonment for throm-
bosis did not differ between the Intervention and Ob-
servation groups (Fig. 3 and Table 2). In contrast, the
risk of access loss because of infection was greater in
the Intervention group than in the Observation group
(unadjusted hazard ratio 6.13, CI 1.14–33.10, P = 0.04)
(Fig. 4 and Table 2). However, the absolute number of
grafts lost to infection was small: six in the Intervention
group, and three in the Observation group. The increased
risk of access infection associated with randomization to
the Intervention group persisted after adjustment for co-
variates (hazard ratio 9.57, CI 1.20–76.58, P = 0.03). In the
Intervention group patients with an AV graft infection,
the median time between a prophylactic access procedure
and a graft infection was 54 days (range 15–158 days).
Thrombotic events
Thrombosis rates were 0.89 and 1.03 per patient-year
in the Intervention and Observation groups, respectively
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SVPR ≥0.4
(N = 184)
Ineligible for enrollment (N = 73)
Language or comprehension barrier (N = 37)
Anticipated noncompliance, medical care
elsewhere, or modality change (N = 28)
Reduced life expectancy (N = 5)
Contrast allergy (N = 3)
Refused enrollment (N = 47)
Randomized (N = 64)
Intervention group
(N = 32)
Observation group
(N = 32)
Withdrew prior to 1st
diagnostic angiogram (N = 4)
Withdrew after ≥1 diagnostic
angiograms (N = 2)
Lost to follow-up (N = 4)
Died (N = 4)
Access abandoned (N = 14)
Still active in study at study
close (N = 4)
Withdrew (N = 0)
Lost to follow-up (N = 2)
Transplanted (N = 1)
Died (N = 2)
Access abandoned (N = 14)
Still active in study at
study close (N = 13)
Fig. 1. Study enrollment and follow-up in the two treatment groups. Loss to follow-up occurred because of transfer to other dialysis facilities.
(Table 4). The proportion of patients with a thrombotic
event was greater in the Observation group (72%) than
in the Intervention group (44%) (P = 0.04). Two of the
25 thrombotic events (8%) in the Intervention group oc-
curred following identification of elevated SVPR but be-
fore performance of the scheduled angiogram. The pro-
portion of thromboses that could not be resolved with
PTA or surgical thrombectomy did not differ in the In-
tervention and Observation groups (0.20 vs. 0.23, P =
0.10). An arterial stenosis was not identified in any of the
Intervention group patients with thrombosis.
Access procedures
Sixty-five AV graft angiograms were performed in the
Intervention arm patients, yielding a prophylactic angiog-
raphy rate of 2.3 per patient-year. A stenosis ≥50% at or
near the venous anastomosis was evident in 60 of the 65
angiograms, yielding a 92% specificity of SVPR ≥0.4 for
venous anastomosis stenosis. A residual stenosis of ≥50%
was evident after PTA in 14% of the prophylactic proce-
dures in the Intervention group patients. Subsequent sur-
gical repair or revision was performed for 75% of these
residual stenoses. Of the 5 patients with elevated SVPR
but negative angiogram, and thus, no PTA, two had a
thrombotic event after the angiogram: one at 74 days, and
the other at 298 days. Procedures to repair stenoses or re-
store patency (radiologic or surgical) occurred at rates of
3.1 per patient-year and 1.1 per patient-year in the Inter-
vention and Observation groups, respectively (rate ratio
2.75, 95%CI 1.93–3.96, P < 0.001) (Table 4). Among pa-
tients with access abandonment for any reason, the mean
number of access procedures performed during study
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Table 1. Baseline characteristics of the randomized patients
Intervention Observation
group group
(N = 32) (N = 32) P value
Patient characteristic
Age years 58 ± 17 60 ± 12 0.55
Male % 47 81 0.008
Black % 88 94 0.67
Body weight kg 74.5 ± 19.4 83.1 ± 20.9 0.09
Diabetes mellitus % 63 47 0.32
PVD % 38 25 0.42
Hemoglobin g/dL 11.4 ± 1.2 11.2 ± 1.5 0.51
Serum albumin g/dL 4.0 (2.9 – 4.4) 4.0 (3.2 – 4.7) 0.78
Warfarin use % 19 22 1.0
ACE inhibitor use % 22 28 0.77
URR % 71.9 ± 7.7 70.4 ± 6.5 0.43
AV graft characteristic
Forearm graft % 34 53 0.21
Graft age days 321 (57–1709) 350 (44–1852) 0.98
Graft age <3 months % 6 9 0.33
No previous procedure % 34 28 0.79
Abbreviations are: PVD, peripheral vascular disease; ACE, angiotensin-
converting enzyme; URR, urea reduction ratio. Values are expressed as mean ±
SD or medians with ranges unless otherwise indicated.
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Fig. 2. Time to AV graft abandonment. Log-rank 2.0; P = 0.50.
participation before abandonment was 3.4 in the Inter-
vention group and 2.8 in the Observation group. Among
patients whose accesses were abandoned because of
thrombosis, the mean number of procedures before aban-
donment was 4.7 in the Intervention group and 2.7 in the
Observation group.
Access-related adverse events
AV graft rupture occurred in one patient in the In-
tervention group and two patients in the Observation
group. The rupture event in the Intervention group pa-
tient occurred during prophylactic angioplasty. The rup-
ture events in both Observation group patients occurred
Table 2. Risk of access abandonment associated with prophylactic
stenosis repair
Hazard ratioa 95% CI P Value
Unadjusted analysis
Abandonment for any reason 1.75 0.80–3.82 0.16
Abandonment for thrombosis 0.65 0.22–1.91 0.44
Abandonment for infection 6.13 1.14–33.10 0.04
Adjusted analysisb
Abandonment for any reason 2.91 1.17–7.20 0.02
Abandonment for thrombosis 1.11 0.33–3.72 0.87
Abandonment for infection 9.57 1.20–76.58 0.03
aThe reference group is the Observation arm.
bThe variables included were sex, diabetes mellitus, peripheral vascular disease,
and location of access (forearm or upper arm).
Table 3. Reasons for access abandonment
Intervention group Observation group
(N = 32) (N = 32)
Thrombosis N (%) 5 (16) 11 (34)
Infection N (%) 6 (19) 3 (9)
Steal syndrome N (%) 1 (3) 0
Pseudoaneurysm N (%) 1 (3) 0
Graft rupture N (%) 1 (3) 0
Total N (%) 14 (44) 14 (44)
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Fig. 3. Time to AV graft abandonment for thrombosis. Log-rank 0.6;
P = 0.43.
in the setting of graft infection. One Intervention group
patient had minor extravasation of contrast that was ev-
ident immediately after angioplasty but resolved with-
out intervention. One Intervention group patient devel-
oped vascular steal syndrome after stenosis repair and
required AV graft removal. None of the patients had a
reaction to the contrast agent, and none had bleeding af-
ter angiogram and/or angioplasty. Requirement for cen-
tral venous catheter placement did not differ significantly
between the Intervention and Observation groups
(Table 4).
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Fig. 4. Time to AV graft abandonment for infection. Log-rank 5.5;
P = 0.02.
Ten patients (six in the Intervention arm, four in the
Observation arm) died either during study participation
or within three months after reaching the primary end
point of access abandonment. Five of the deaths were
considered access-related because of either an etiologic
or a temporal association with a vascular access event.
The access-related deaths in the Intervention arm pa-
tients included: (1) death caused by ischemic bowel one
day after creation of a new AV graft in a patient with
unsuccessful attempts to restore patency after a throm-
botic event; and (2) death from hyperkalemia two months
after access abandonment for graft infection. The hyper-
kalemic death was considered access-related because it
occurred during a transition from hemodialysis to peri-
toneal dialysis that was necessitated by loss of the AV
graft. The access-related deaths in the Observation Arm
patients included: (1) death from aspiration pneumonia
two weeks after AV graft abandonment for infection; (2)
death from sepsis after mechanical thrombolysis of an AV
graft; and (3) death from esophageal rupture one month
after access abandonment because of inability to restore
patency after a thrombotic event. This death was consid-
ered access-related because the esophageal injury was felt
to have occurred during endotracheal tube placement for
general anesthesia used during placement of a new AV
graft.
Adherence to study protocol
Six angiograms that were indicated based on SVPR ele-
vation were not done because of patient withdrawal from
the study (N = 4), patient refusal (N = 1), or death caused
by cardiac arrest before the scheduled procedure (N =
1). Angioplasty of access stenosis was performed in the
absence of thrombosis in two patients in the Observation
group. The indications for the Observation group proce-
dures were upper extremity swelling in one patient, and
inability to achieve an adequate dialysis machine blood
flow in the other patient.
DISCUSSION
We performed a randomized trial comparing two
strategies for managing hemodialysis AV graft dysfunc-
tion, and found that graft survival was not improved by
prophylactic repair of access stenosis. Our findings ap-
pear to be in direct contrast with results of previous stud-
ies that showed reductions in access replacement rates
with prophylactic stenosis repair triggered by routine ac-
cess monitoring. Schwab et al found that access replace-
ment rates decreased by 73% after the implementation
of dynamic venous pressure monitoring, and Besarab et
al found a 76% reduction in access replacement rates
with the use of static venous pressure monitoring [3, 4].
However, neither of these studies was randomized, and
both utilized historical control groups from an era when
restoration of access patency after thrombosis may have
been attempted less often than it is currently. Our throm-
bosis rates and access abandonment rates were higher
than those reported in previous studies because we stud-
ied high-risk patients (i.e., only those patients with ele-
vated SVPR).
A previous randomized trial of prophylactic repair of
AV graft stenosis found no improvement in the primary
patency rate with prophylactic access repair, except in a
subset analysis of “virgin” grafts, and did not report on
cumulative access survival [10, 11]. This study was similar
to ours in that it enrolled only high-risk patients. Eligible
patients were required to have at least a 50% stenosis
identified by color-flow duplex imaging, and confirmed
by angiography. The patients were then randomized to ei-
ther Intervention or Observation. The primary outcome
measure was graft thrombosis or impaired flow such that
dialysis was not feasible. Sixty-four patients were enrolled
in the study. There was no difference between treatment
groups in graft patency at either six or 12 months [10].
A subsequent paper reported the results of a subgroup
analysis of 21 patients with grafts with no previous sur-
gical revision, angioplasty, or thrombectomy [11]. In this
subgroup, patients randomized to the to the Interven-
tion group had a significant prolongation of graft patency
(P = 0.0349). Subset analysis of the virgin grafts in our
study did not reveal a difference in access survival be-
tween the Intervention and Observation groups, although
demonstration of such a difference may have been pre-
cluded by the small size (N = 19) of the virgin graft subset
(data not shown).
In a recently published study, Ram et al random-
ized 101 patients to either (1) a control group in which
referral for angioplasty was made based on clinical
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Table 4. Access event rates (# per patient-year)
Intervention Observation Rate
group group ratio 95% CI P Value
Angiography in absence of thrombosis 2.3 0.04 52.87 14.06–445.79 <0.001
Stenosis repair or patency restoration 3.1 1.1 2.75 1.93–3.96 <0.001
Thrombosis 0.89 1.03 0.86 0.51–1.43 0.57
Infection 0.21 0.07 3.25 0.69–20.11 0.10
Central venous catheter 0.64 0.41 1.54 0.76–3.10 0.19
criteria, including prescribed pump speed not attained,
high dynamic venous pressure observed by dialysis care
providers, excessive bleeding postdialysis, or swelling of
the extremity; (2) a flow group in which referral for an-
gioplasty was made if monthly measurement of access
blood flow revealed a blood flow <600 mL/min; or (3)
a stenosis group in which referral for angioplasty was
made if a stenosis >50% was detected by quarterly ul-
trasounds [12]. There were no significant differences in
graft survival in the three groups, and although there was
a trend toward delayed first thrombosis in the ultrasound
group (P = 0.12), this was associated with an angioplasty
rate two to three times that in the other groups. As com-
pared with our study, the population was lower risk be-
cause graft dysfunction was not a criterion for study en-
try, and the percentage of patients who had not had a
previous procedure on their grafts was higher (67% vs.
31%). Nevertheless, the thrombosis rates in this study
were still quite high (29% to 53%). The authors note that
the higher rates of preemptive angioplasty in the flow and
ultrasound groups were not associated with reduced rates
of thrombosis or improved graft survival, and question
whether angioplasty of a stable stenosis might shorten
graft life by stimulating neointimal hyperplasia.
We did find a trend toward a reduction in access aban-
donment for unresolvable thrombosis in the Intervention
group, and it is possible that this difference would have
been greater if fewer accesses in the Intervention group
had been lost to infection (Fig. 3). Although the over-
all thrombosis rates did not differ markedly between the
two treatment groups, a smaller proportion of patients
in the Intervention group had a thrombotic event during
the study period. Only 8% of the thrombotic events in
the Intervention group occurred during the interval be-
tween identification of the SVPR elevation and the per-
formance of a diagnostic angiogram, suggesting that delay
in performing the intervention was not a major factor in
the thrombosis outcome. It is also unlikely that failure
to adequately repair identified stenoses led to the lack
of reduction in thrombosis rates with prophylactic repair
because radiographic evidence of stenosis resolution was
present after completion of the radiologic or surgical re-
pair procedures in the majority of cases. It is noteworthy
that only 31% of patients in the Observation group had
a thrombotic event within 100 days of the first SVPR
elevation, indicating that in a substantial proportion of
patients, SVPR elevation is not associated with thrombo-
sis in the short-term. Given the high specificity of SVPR
elevation for radiographically evident venous anastomo-
sis stenosis demonstrated in the Intervention group, this
finding suggests that many stenoses do not result in graft
thrombosis.
It is possible that we would have seen a reduction in
thrombotic events with prophylactic repair had we used
a different screening test for identifying stenoses. Indeed,
we have found that despite high sensitivity and specificity
for venous anastomosis stenosis, static venous pressure
has poor utility as a predictor of thrombosis [13]. Com-
parisons of venous pressure and access blood flow as pre-
dictors of access thrombosis have yielded varied results.
May et al directly compared several access monitoring
methods, and concluded that a reduction in access blood
flow identified by either ultrasound dilution or Doppler
ultrasound is a better predictor of AV graft thrombosis
than is elevated dynamic venous pressure [14]. McCar-
ley et al observed lower thrombosis rates while using ac-
cess blood flow monitoring to trigger intervention than
while using dynamic venous pressure monitoring [8]. In
contrast, Smits et al found similar thrombosis rates using
either access blood flow monitoring or venous pressure
monitoring strategies [15], and three other analyses sug-
gest that access blood flow has poor diagnostic accuracy
for subsequent thrombosis [16–18]. In a recent trial, Moist
et al found similar graft outcomes in 112 patients ran-
domized to monitoring with either monthly blood flow
measurements or dynamic venous pressure and clinical
examination [19]. There was no difference between the
groups in time to first thrombosis, and the rates of graft
thrombosis per patient year were 0.51 in the flow moni-
toring group and 0.41 in the venous pressure-monitoring
group. The higher rates of thrombosis occurred in spite of
a higher rate of preemptive intervention in the flow group
than the venous pressure group (0.93 vs. 0.61 per patient-
year). The lack of benefit of increased angioplasty rates
in this study and in the study by Ram et al [12] is consis-
tent with our finding of a lack of utility of prophylactic
angioplasty compared with observation with angioplasty
at the time of graft thrombosis.
Our primary end point was graft abandonment, and did
not include surgical revision of the venous anastomosis.
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Because one of the goals of prospective monitoring may
be to preserve the venous anastomosis and avoid extend-
ing the graft proximally, some might consider avoidance
of surgical revision as a potential benefit of prophylac-
tic angioplasty. If we had included surgical revision of
the venous anastomosis in our end point definition, an
additional six patients, five of whom were in the Inter-
vention group, would have met criteria for the primary
end point. Therefore, expanding the definition of our end
point would further weaken any benefit of prophylactic
repair.
Our finding that access loss resulting from AV graft in-
fection was more freguent in the Intervention group than
the Observation group was unexpected. Most of the in-
fections occurred several weeks or months after an inter-
vention, making it unlikely that introduction of bacteria
during the procedure was the source of the infection. An
alternative explanation is that angioplasty-induced dam-
age to the blood vessel increases the avidity of the graft
for bacteria, and thereby predisposes to graft infection
in the setting of what would otherwise be clinically in-
significant episodes of bacteremia. An obvious source of
low-level bacteremia is the thrice-weekly graft cannula-
tion for dialysis.
An increased risk of graft infection with access repair
procedures is supported by comparisons of the virgin and
nonvirgin grafts. None of the nine infections in our study
occurred in Observation group patients with virgin grafts.
That is, infections occurred only in those grafts that had
been subjected to a procedure either before or during the
study. An increased risk of infection with access interven-
tion is also suggested by a study comparing graft survival
rates in two dialysis centers, one of which had a monitor-
ing and prophylactic repair program. An increased rate
of graft loss caused by infection occurred in the facility
that practiced prophylactic access repair [abstract; Mur-
ray BM, Racjzak SL, J Am Soc Nephrol 12:A298, 2001].
Other studies of the impact of access monitoring and pro-
phylactic repair on thrombosis rates and/or cumulative
access survival did not report infection rates.
The strengths of our study include its randomized de-
sign, the prospective collection of outcome data, a high
adherence to the treatment protocol, and the perfor-
mance of venous pressure measurements by a single
individual. The study also has limitations. Despite ran-
domization, the two treatment groups were unbalanced
with respect to sex, and had statistically nonsignificant
differences in other potentially important characteris-
tics. However, the findings of the study did not change
after adjustment for the unbalanced variables. Because
the study was performed at only two centers, the results
may not be able to be generalized to other settings, and
the possibility that center-related factors were responsi-
ble for the findings cannot be excluded. Finally, neither
the patients nor investigators were masked to treatment
group assignment. Decisions regarding access abandon-
ment were not made by study personnel, but by treat-
ing physicians, who may or may not have been aware
of the patient’s participation in the study. It is possible
that knowledge of treatment assignment may have bi-
ased the decision by treating physicians about whether
or not to abandon the access. However, for the results
of the study to indicate lack of benefit from prophylac-
tic interventions, one would have to speculate that deci-
sions to abandon the access were more likely to occur in
the Intervention group. The finding that participants in
the Intervention group underwent more procedures be-
fore access abandonment than those in the Observation
group makes it unlikely that a less aggressive approach
to access salvage was applied to the Intervention group
patients.
CONCLUSION
We found that repair of stenosis identified by monthly
static venous pressure monitoring reduced the incidence
of thrombosis, but did not prolong AV graft survival or
reduce overall thrombosis rates. These results, together
with those of Lumsden et al [10] and Ram et al [12], sug-
gest that if prophylactic intervention provides a benefit,
it is probably much less than that suggested by previ-
ous uncontrolled trials. If these findings are confirmed by
other randomized trials, recommendations for prophy-
lactic stenosis repair may need to be reconsidered. The
possibility that repeated access repair procedures predis-
pose to graft infection warrants further investigation.
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